The normal platelet count in human blood is 150,000-400,000/?L, and these platelets are responsible for efficient hemostatic surveillance and bleeding mitigation in the body. Thrombocytopenia (TCP, low platelet count) is a condition caused by a decrease in platelet production, increase in platelet destruction or consumption, or increase in splenic sequestration. The age-adjusted prevalence of immune thrombocytopenic purpura (ITP) is estimated to be 9.5 per 100,000 persons in the USA, while drug-induced TCP affects 1-2 per 100,000 persons. The majority (>95%) of TCP cases result from autoimmune disorders or are induced by chemo- and radiotherapies as well as other pharmaceuticals. At platelet counts <50,000/?L, surgical procedures are complicated by high bleeding risks and any minor injury may lead to excessive bleeding. At counts <10,000/?L, spontaneous bleeding becomes a major concern. Therefore, frequent therapeutic and prophylactic platelet transfusions are required to increase platelet counts and mitigate bleeding risks. However, the availability of natural platelet products is severely limited by a near-static pool of donors and a very short shelf-life (3-5 days) due to high risks of bacterial contamination and storage-related platelet activation and degranulation. Therefore, there exists a significant unmet clinical need for a therapeutic agent that can mitigate bleeding complications intravenously in TCP patients, while allowing reduced contamination and long shelf-life without compromising function. To this end, we have developed a synthetic hemostatic nanotechnology, called SynthoPlateTM, that mimics platelet?s ability to adhere and aggregate specifically at a site of injury in the body. This technology has demonstrated platelet-mimetic hemostatic functions in vitro as well as in vivo in proof-of-concept murine and porcine models of bleeding. Building on this preliminary data, this proposal aims to establish the minimum and maximum effective doses of SynthoPlateTM needed to enhance clotting properties in vitro and mitigate bleeding in vivo in a mouse model of TCP. Success with the aims of this Phase I SBIR proposal will establish SynthoPlateTM as an innovative intravenously transfusable technology to mitigate bleeding complications in TCP. Furthermore, successful therapeutic demonstration with SynthoPlateTM in TCP mice will allow subsequent dosing, safety, toxicity and efficacy studies with GMP-manufactured SynthoPlate in large animal models, thus allowing IND-enabling studies towards clinical development, envisioned in Phase II.

Public Health Relevance

Thrombocytopenia is a condition characterized by low platelet counts; patients with thrombocytopenia are at risk of excessive, uncontrollable bleeding. The current standard of care is transfusion with donor platelet products to mitigate bleeding risks. However, donor platelets are expensive, carry significant risk of infections, have variable hemostatic efficacy, and have very short shelf life (3-5 days). Our innovative SynthoPlateTM technology can mimic platelet?s hemostatic functions while providing advantages of large-scale production and sterilizability to reduce contamination risk and ensure long shelf life.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Warren, Ronald Q
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Haima Therapeutics, LLC
United States
Zip Code